Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

31 results about "Molecular classification" patented technology

Molecular taxonomy is the classification of organisms on the basis of the distribution and composition of chemical substances in them.

Molecular classification prediction method based on molecular biomarkers and images

The invention discloses a molecular classification prediction method based on molecular biomarkers and images, and relates to the technical field of medical image processing. Comprising the following steps: constructing a molecule and image matching correlation analysis model; training by using the training data set; the channel number of the target preoperative medical image data is increased through the feature extraction convolution block; a space matching relation between an image and a molecular biomarker in the processed target preoperative medical image data is established through an image molecule fine granularity insight module, and a feature map after the space relation is established is obtained through a space molecule mapping map output module; adjusting the feature map into a corresponding molecular channel through a space molecular mapping map output module to obtain a space molecular mapping map; and pooling the spatial molecular mapping map through a global average pooling module, and activating and calculating a molecular category prediction probability through Sigmoid to obtain a molecular classification prediction result. According to the invention, the spatial relation between molecules and images is established.
Owner:FOURTH MILITARY MEDICAL UNIVERSITY

Hereditary cancer genes

The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.
Owner:MYRIAD GENETICS INC

Random forest classifier and molecular subtype classifier for molecular typing of esophageal squamous carcinoma and construction method of random forest classifier and molecular subtype classifier

The invention belongs to the technical field of bioinformatics and computational biology, and relates to a random forest classifier and a molecular subtype classifier for esophageal squamous cell carcinoma molecular typing and a construction method. The number of molecular subtypes is four, and the molecular subtypes are respectively ECMS 1, ECMS 2, ECMS 3 and ECMS 4. The method is characterized in that: ECMS 1: when a metabolic pathway is abnormal and NFE2L2 is activated, an NFE2L2 inhibitor is selected as a drug; eCMS 2: tumor classical signal pathway is up-regulated, and methylation degree is low; eCMS 3 has the advantages of few copy number variation events, low tumor mutation load and high PD-1 expression, and is beneficial to immunosuppressor treatment; eCMS 4: the epithelial-mesenchymal transition pathway is activated, the overall survival rate and disease-free survival rate are low, and epithelial-mesenchymal transition and VEFG inhibitor treatment are benefited. According to the invention, heterogeneity of esophageal squamous carcinoma is analyzed, and each typing system is unified, so that molecular typing is realized, and popularization is easier.
Owner:SHANXI MEDICAL UNIV +1

A breast cancer classification method based on Piezo1 expression

PendingCN122084899AProteomicsGenomicsBreast cancer classificationMolecular classification
This invention discloses a breast cancer classification method based on Piezo1 expression. After obtaining tumor tissue samples from patients, the method detects the Piezo1 protein expression level using immunohistochemistry and classifies them into high-expression and low-expression types according to a validated scoring standard. This classification result guides individualized treatment, with high-expression patients recommended for treatment regimens including inhibitors of mechanotransmission pathways. By integrating tumor mechanotransmission characteristics into the clinical classification system, this invention can identify a subgroup of breast cancer driven by an abnormal mechanotransmission microenvironment that cannot be distinguished by traditional molecular classification. This not only improves and supplements the existing classification framework, making the understanding of breast cancer heterogeneity more comprehensive, but also more accurately predicts the invasiveness, metastasis potential, and poor prognostic risk of these patients.
Owner:JINZHOU MEDICAL UNIV

Signatures for predicting cancer immune therapy response

PendingUS20260063636A1Health-index calculationMicrobiological testing/measurementMolecular classificationOncology
This disclosure generally relates to a molecular classification of cancer and particularly to molecular markers for predicting response to cancer therapy, including cancer immune therapy, and methods of use thereof.
Owner:MYRIAD GENETICS INC

Molecular classification of UTUC and construction of prognostic prediction model

The present invention discloses a molecular typing method for upper urinary tract urothelial carcinoma (UTUC), which performs molecular typing of UTUC based on the circRNA abundance expression characteristics of UTUC patients. The present invention also discloses UTUC prognosis prediction markers based on the above typing method and a screening method thereof, as well as a UTUC prognosis prediction model and a construction method. The present invention uses transcriptome sequencing data of UTUC patients to analyze and obtain circRNA abundance expression data of UTUC patients, and establishes a UTUC molecular typing method based on circRNA abundance expression characteristics by screening and clustering circRNAs related to UTUC prognosis, and further constructs a UTUC prognosis prediction model using circRNA as a marker, which helps to improve the accuracy of prognosis prediction for UTUC patients.
Owner:SHANGHAI RENDONG MEDICAL LAB CO LTD +1

Staphylococcus capitis MLST molecular typing method

The application discloses a molecular typing method of Staphylococcus capitis, and first establishes an operation technology for molecular typing of Staphylococcus capitis by using a multi-locus sequence typing system (MLST). Seven conservative gene fragments are confirmed by screening, all known Staphylococcus capitis genomes are typed based on the combined sequences, ST types and CC types are defined, and a system evolution tree based on core genome SNP differences is compared, so that reliable typing results can be obtained. Seven pairs of PCR primers are designed and verified, and the Staphylococcus capitis can be typed by MLST. The seven conservative gene combinations and amplification primers used in the typing technology are used for the first time, and the PCR reaction system and conditions are optimized by the inventors. The technical process can be used for molecular classification and epidemiological monitoring of Staphylococcus capitis.
Owner:ZHEJIANG UNIV

Molecular Classification Method Based on Hash Algorithm

ActiveCN115331754BMolecular designChemical machine learningMolecular classificationAlgorithm
The present invention discloses a molecular classification method based on a hash algorithm, which includes obtaining molecules with known classifications and constructing molecular structure diagrams; calculating the vector representations of vertices in the diagrams; obtaining the adjacent node vectors and representations of each vertex and splicing them to obtain the hash code vector representations of each vertex; adding up all the hash code vector representations of the vertices; obtaining the vector representations of each molecular structure diagram; calculating the similarity between any two molecular structure diagrams and constructing a kernel matrix; training to obtain a molecular graph classifier; obtaining the similarity between the molecular structure diagram of the molecule to be classified and the known molecular structure diagrams, and inputting it into the molecular graph classifier to obtain the classification result. The method of the present invention avoids the massive parameter learning in graph neural networks and no longer relies on expensive high-end hardware. It can significantly reduce the time overhead on the premise of meeting the molecular classification accuracy, and is especially suitable for classification tasks in the scenario of large-scale molecular graph datasets. Moreover, it has high reliability, good precision and high efficiency.
Owner:CENT SOUTH UNIV

Molecular classifier for detecting gastric cancer miRNA as well as preparation method and application of molecular classifier

The invention provides a molecular classifier for detecting gastric cancer miRNA. A preparation method of the molecular classifier comprises the following steps: depositing a PABA modification layer on the surface of a screen-printed electrode; activating carboxyl on the surface of the para aminobenzoic acid modification layer by adopting an EDC / NHS composite system; carrying out amination modification on an MXene material, and coating the surface of the activated para aminobenzoic acid modification layer with the modified MXene material to form an MXene functional layer; depositing gold nanoparticles on the surface of the MXene functional layer to obtain an electrochemical activity sensing interface; a signal reporter molecule is combined with an aptamer probe, the signal reporter molecule is a DNA tetrahedron-methylene blue complex, and the combined complex is dropwise added on the surface of an electrochemical activity sensing interface, so that the aptamer probe is combined on the surface of the electrochemical activity sensing interface. The molecular classifier can be used for preparing gastric cancer miRNA detection products, and the problems that in the prior art, a classifier is high in complexity and high in signal leakage risk are solved.
Owner:NANJING UNIV OF SCI & TECH

Molecular classification diagnosis system for diagnosing prostatic cancer through multi-target combined weight system

The invention discloses a molecular classification diagnosis system for diagnosing prostatic cancer through a multi-target combined weight system, and belongs to the technical field of biological medicine. The method comprises the following steps: establishing a mathematical logic relationship among multiple targets through data training by utilizing an existing clinical database containing information of patients with prostatic cancer and benign hyperplasia, namely, a weight ratio of four biomarkers related to prostatic cancer to diagnosis of prostatic cancer, and obtaining a weight diagnosis formula for classification of prostatic cancer and benign hyperplasia of prostatic; a weight detection system is established, a DNA tetrahedral framework nucleic acid dimer structure is used as a signal output substrate, and a multi-target combined intelligent diagnosis system is constructed by pricing and modifying different signal molecules on a signal output probe, so that precise classification of prostatic cancer and benign prostatic hyperplasia is realized, and the accuracy of early diagnosis of prostatic cancer is improved.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Molecular classification method based on heterogeneous graph embedding

ActiveCN120355989AEnergy efficient computingNeural learning methodsMolecular classificationAlgorithm
The invention provides a molecular classification method based on heterogeneous graph embedding, and belongs to the technical field of molecular classification. Comprising the following steps: performing simplex extraction on a heterogeneous graph; processing the structure information of the heterogeneous graph based on the extracted simplex to obtain local and global information enhancement operators; processing feature information of the heterogeneous graph based on the extracted simplex to obtain a feature matrix; based on the local and global information enhancement operators and the feature matrix, performing Hash iteration on the heterogeneous graph to obtain graph-level embedding; and performing molecular classification on the graph-level embedding to obtain a molecular classification result. According to the method, the simplex algorithm and the Hash algorithm are combined, so that high-order interaction information and heterogeneous features can be effectively captured, the calculation efficiency is remarkably improved, and an efficient and extensible solution is provided for heterogeneous graph analysis.
Owner:CENT SOUTH UNIV

Molecular dynamics simulation mean square displacement accurate calculation method based on multiphase identification

The invention provides a molecular dynamics simulation mean square displacement accurate calculation method based on multi-phase state recognition, and the method comprises the steps: precisely classifying target molecules in a system into four states: near-impurity target molecules, target molecules in hydrates, target molecules in clusters and target molecules in a liquid phase, and employing a multi-stage screening strategy in the classification process, and the independence of each type of molecules is ensured. Traditional MSD calculation only requires molecules to be in a target phase state in a start frame and an end frame, but a middle frame may undergo phase change, such as entering hydrate from a liquid phase, resulting in deviation of a calculation result from an intrinsic diffusion behavior. According to the method, the occurrence state of the molecules in the whole simulation process is tracked, the state needing to be calculated is accurately found out, it is ensured that the MSD only reflects the continuous diffusion process of the molecules in the pure liquid phase through a state continuous verification mechanism, phase change interference is eliminated, and targeted MSD calculation is conducted.
Owner:CHINA UNIV OF PETROLEUM (EAST CHINA)

Therapeutics for breast cancer based on molecular classification

PCT designated stageWO2025217231A1Organic active ingredientsTherapiesMolecular classificationOncology
Systems and methods for assessment of breast cancer are provided. The assessment can stratify breast cancer individuals based on genomic archetypes of the cancer. The assessment can be utilized as a diagnostic to determine a treatment regimen that would benefit a patient based on the genomic archetypes. The treatment regimen can include a targeted treatment that targets the molecular characteristics that are associated with the genomic archetype. A targeted treatment can be optionally combined with chemotherapy, immunotherapy, hormonal therapy, or other therapies for treating breast cancer.
Owner:THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIV

Small cell lung cancer molecular subtype and application thereof

The invention relates to a small cell lung cancer molecular subtype and application thereof. Based on data of transcriptomics, proteomics and phosphorylation, unsupervised clustering analysis is carried out by using NMF, four subtypes of SCLC are found, analysis is carried out in combination with molecular characteristics of multiple omics subtypes and in-vivo experiments, an accurate treatment scheme of the SCLC is further disclosed, the treatment specificity of the subtypes of the SCLC is clarified, and the treatment effect of the subtypes of the SCLC is improved. According to the present invention, the defects of the current SCLC molecular typing treatment are made up, more treatment targets are provided for the SCLC treatment so as to achieve the precise treatment, more hopes are provided for the health of patients, and the good application prospects are provided.
Owner:SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & CONTROL INSTITUTE)

A molecular classification diagnosis system for diagnosing prostate cancer through a multi-target combined weight system

ActiveCN121617483BMedical data miningBiostatisticsMolecular classificationSignalling molecules
The application discloses a molecular classification diagnosis system for diagnosing prostate cancer through a weight system combined with multiple targets, and belongs to the technical field of biological medicine. By using an existing clinical database containing information of prostate cancer and benign hyperplasia patients, a mathematical logic relationship between multiple targets is established through data training, that is, weight matching of four prostate cancer related biomarkers for prostate cancer diagnosis, so that a weight diagnosis formula for classifying prostate cancer and prostate benign hyperplasia is obtained; a weight detection system is established, a DNA tetrahedral framework nucleic acid dimer structure is used as a signal output base, different signal molecules are modified on a signal output probe, an intelligent diagnosis system combined with multiple targets is constructed, and accurate classification of prostate cancer and prostate benign hyperplasia is realized, thereby improving the accuracy of early diagnosis of prostate cancer.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Method for accurate calculation of mean square displacement based on polytype identification of molecular dynamics simulation

The application provides a method for accurately calculating mean square displacement (MSD) of molecular dynamics simulation based on multi-phase state identification, which accurately classifies target molecules in the system into four states: near impurity target molecules, target molecules in hydrates, target molecules in clusters and target molecules in liquid phase. The classification process adopts a multi-stage screening strategy to ensure the independence of each type of molecule. Traditional MSD calculation only requires molecules to be in the target phase state at the start and end frames, but the intermediate frame may undergo phase transition, such as entering the hydrate from the liquid phase, resulting in a deviation of the calculation result from the intrinsic diffusion behavior. The application tracks the occurrence state of the molecule during the entire simulation process, accurately finds the state that needs to be calculated, and ensures that MSD only reflects the continuous diffusion process of the molecule in the pure liquid phase through a state persistence verification mechanism, excluding the interference of phase transition, and performing targeted MSD calculation.
Owner:CHINA UNIV OF PETROLEUM (EAST CHINA)

A self-supervised molecular classification method based on a deep learning model

The application is suitable for the technical field of molecular classification, and provides a self-supervised molecular classification method based on a deep learning model, which comprises the following steps: step 1, an original molecule is processed into a form represented by an adjacency matrix and a feature matrix, and then represented by a graph; step 2, the graph is taken as an input of a graph neural network module, local features of the molecule are obtained, and the properties of the molecule are predicted; and step 3, a standard binary classification cross-entropy loss function is used to adjust a self-supervised learning task between a positive sample pair and a negative sample pair. The method has important significance for screening candidate drugs for specific diseases, especially for a new molecular data set without labels, and can achieve the purpose of rapid classification. Not only can the method replace time-consuming manual labeling of researchers and shorten the time to a short range, but also can control errors to a certain extent, so that real-time performance and accuracy are ensured.
Owner:JILIN UNIVERSITY

MIBC multi-omics molecular typing method and prediction system

The present invention discloses a multi-omics molecular typing method for muscle-invasive bladder cancer. The method performs cluster analysis on muscle-invasive bladder cancer based on the transcriptome gene abundance expression characteristics and protein abundance expression characteristics of muscle-invasive bladder cancer patients to obtain molecular subtypes of muscle-invasive bladder cancer associated with prognosis. The present invention also discloses a method and system for predicting multi-omics molecular subtypes of muscle-invasive bladder cancer. The present invention integrates and screens the abundance expression data of transcriptomes and proteomes, and uses a multi-omics consistency clustering method to determine the multi-omics molecular typing of muscle-invasive bladder cancer, and constructs a molecular subtype prediction system, thereby facilitating the accurate prediction of the multi-omics molecular subtypes of muscle-invasive bladder cancer, indicating the prognosis of patients, and providing an effective reference for precision medicine.
Owner:SHANGHAI RENDONG MEDICAL LAB CO LTD +1

Molecular typing method and system for chordoma and application of molecular typing method and system

InactiveCN119291102AAccurate classification and diagnosisAccurate Prognostic EvaluationComponent separationBiostatisticsChordomaProtein expression profile
The invention belongs to the technical field of biomedicine technologies, and particularly relates to a chordoma molecular typing method and system and application thereof. The invention provides a chordoma molecular typing method which comprises the following steps: performing protein expression analysis on a protein sample of a patient to generate protein expression profile data; performing clustering analysis on the basis of the protein expression profile data, analyzing specific protein expression characteristics obtained by clustering analysis, and identifying molecular subtypes of chordoma; specific protein expression characteristics are provided for each molecular subtype. The invention further provides a chordoma molecular typing system or device. The chordoma molecular typing system or device comprises a proteomics analysis module, a molecular subtype typing module and a typing output module. The methods, systems, or devices identify bone microenvironment dominant, mesenchymal derived, and mesenchymal epithelial transformations, thereby assessing clinical characteristics and prognosis of chordoma of different molecular subtypes.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL

A new species of guizhou macropes, its dna standard detection gene and application

PendingCN122642379ARhabditis sp.Molecular classification
The application belongs to the technical field of new species gene detection of insects, and particularly relates to a Guizhou large-mouthed worm new species, a DNA standard detection gene thereof and application. The Guizhou large-mouthed worm is separated from a freshwater environment in Guizhou province of China, the worm can actively prey on Rhabditis sp. nematodes, and the Guizhou large-mouthed worm is identified by combining traditional morphological identification and molecular classification methods, so that the accuracy of species identification can be ensured.
Owner:GUIZHOU INST OF BIOTECHNOLOGY (GUIZHOU KEY LAB OF BIOTECHNOLOGY GUIZHOU POTATO RES INST GUIZHOU FOOD PROCESSING RES INST)

Biomarker-based retroperitoneal liposarcoma molecular typing method, system and equipment

ActiveCN119252381AMolecular designMicrobiological testing/measurementRetroperitoneal liposarcomaMolecular classification
The invention provides a retroperitoneal liposarcoma molecular typing method, system and equipment based on biomarkers, the method can divide retroperitoneal liposarcoma into three subtypes based on three genes of KLF6, ECM2 and LMNB2, and a foundation can be laid for molecular typing, prognosis and targeted drug design of retroperitoneal liposarcoma.
Owner:PEOPLES HOSPITAL PEKING UNIV

Panels and methods for treatment of diffuse large b-cell lymphoma

PCT designated stageWO2025213125A1Medical data miningDrug and medicationsAssayMolecular classification
Owner:DANA FARBER CANCER INSTITUTE INC +2

Panels and methods for treatment of diffuse large b-cell lymphoma

PCT designated stageWO2025213122A1Medical data miningDrug and medicationsAssayMolecular classification
Owner:DANA FARBER CANCER INSTITUTE INC +2

Metabolic gene characteristic-based squamous cell carcinoma marker as well as typing and application thereof

According to the application of the metabolic gene marker combination in construction of the squamous cell carcinoma typing model, the gene markers comprise 16 types such as CAD, CYP27B1, SLC44A1, GGT5, GLS, PPT1, GFPT2, NT5E, PADI3, PLA2G7, LPCAT1, SLC16A1, SLC7A7, GMPS, VKORC1 and SLC3A2, and the gene markers are divided into metabolic gene low expression types and metabolic gene high expression types. Through verification, the marker combination can be suitable for squamous cell carcinoma of four different organs, has high general applicability, effectively reduces the research and development cost of independently developing a typing system for SCC cancer species of various organs, provides a uniform molecular typing platform for precise medical treatment of the generic cancer species, not only reduces the detection cost, but also is low in technical threshold, and has wide application prospects. The detection period is shortened, and the clinical application efficiency is improved.
Owner:SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

The invention relates to a malignant hematological tumor chromosome translocation t (5; 8) detection reagent and application thereof

The invention provides a malignant hematological tumor chromosome translocation t (5; 8) and application thereof, and belongs to the technical field of tumor diagnosis. According to the invention, a novel enhancer chromosome translocation is detected in a patient with multiple myeloma, specifically, the enhancer chromosome translocation is formed by reconnecting an upstream sequence formed by fracture of 127798852 site of a chromosome 8 and a downstream sequence formed by fracture of 173708142 site of a chromosome 5. The occurrence of chromosome translocation is verified through PCR and Saner sequencing, a dual luciferase report experiment is utilized to verify that an enhancer has a function of up-regulating gene expression, and a qPCR technology is utilized to verify that up-regulating expression of a CPEB4 gene is caused by chromosome translocation of a patient with multiple myeloma. Therefore, the invention provides a novel detection target and a novel detection mode for molecular typing of multiple myeloma.
Owner:PEKING UNIV

Chemical molecular diagram classification method and equipment based on structure enhancement and medium

The invention discloses a chemical molecule graph classification method and device based on structure enhancement and a medium, and belongs to the technical field of graph machine learning. Aiming at the problem of insufficient utilization of chemical molecule graph structure information, the method comprises the following steps of: 1, acquiring a chemical molecule data set, and constructing a corresponding chemical molecule graph for each chemical molecule in the chemical molecule data set by taking an atom as a node and a chemical bond as an edge; 2, constructing a chemical molecule graph classification model based on structure enhancement, wherein the model comprises three parts of structure enhancement, sub-graph representation and graph classification; and step 3, training and optimizing the graph classification model constructed in the step 2, and performing model performance evaluation and comparative analysis. The structure information of the chemical molecules can be more perfectly captured, and the classification accuracy of the chemical molecules is remarkably improved.
Owner:SHANXI UNIV

Hereditary cancer genes

PendingUS20260176703A1Organic active ingredientsMicrobiological testing/measurementDiseaseMolecular classification
The invention generally relates to a molecular classification of disease predisposition and particularly to molecular markers for cancer predisposition and methods of use thereof.
Owner:MYRIAD GENETICS INC

The invention relates to a multiple myeloma chromosome translocation t (1; 22) detection reagent and application thereof

The invention provides a multiple myeloma chromosome translocation t (1; 22) and application thereof, and belongs to the technical field of disease diagnosis. According to the invention, a novel chromosome translocation is obtained through identification by using a bioinformatics technology, and specifically, an upstream sequence formed by breaking a chromosome 22 at a 39280931 site is reconnected with a downstream sequence formed by breaking a chromosome 1 at a 178385884 site. The enhancer of the chromosome 1 is translocated to the vicinity of the dyed APOBEC3A gene 22 to cause up-regulated expression of potential cancer genes of the APOBEC3A. Thus, the multiple myeloma patient's chromosomal translocation t (1; 22) can be used as a novel detection target in multiple myeloma molecular typing, and can be used for disease diagnosis and prognosis evaluation.
Owner:PEKING UNIV

Peripheral blood metabolite-based diagnostic product for molecular typing of hepatocellular carcinoma

The invention provides a peripheral blood metabolite-based diagnostic product for hepatocellular carcinoma molecular typing, belongs to the field of tumor clinical medicine, and comprises a kit for detecting abundance of metabolite in peripheral blood serum, calculating a single sample gene set enrichment analysis score and predicting hepatocellular carcinoma molecular typing. According to the diagnosis product, rapid molecular typing is carried out on hepatocellular carcinoma by detecting the abundance of metabolites in peripheral blood serum, and different treatment effects of liver cancer patients can be predicted while high accuracy is achieved.
Owner:NANJING DRUM TOWER HOSPITAL

A method and device for molecular typing of colorectal cancer based on immune characteristics

ActiveCN115188415BMedical automated diagnosisProteomicsIntestinal CancerMolecular classification
The present invention relates to a method and device for molecular typing of colorectal cancer based on immune signatures, the method comprising the following steps: obtaining cohort data, gene expression profiles and clinical information data of colorectal cancer; obtaining immune-related characteristics, and obtaining prognosis-related immune signatures from the obtained cohort data, gene expression profiles and clinical information data of colorectal cancer based on the enrichment scores of the immune-related characteristics; performing subtype identification and verification according to the prognosis-related immune signatures; and classifying patient information data according to the obtained subtypes to determine the phenotype of colorectal cancer. Compared with the prior art, the molecular typing of colorectal cancer of the present invention has the advantages of high accuracy and high reliability.
Owner:FUDAN UNIV SHANGHAI CANCER CENT